A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

ClinicalTrials.gov ID: NCT03989414

Public ClinicalTrials.gov record NCT03989414. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Study identification

NCT ID: NCT03989414
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Celgene; Industry
Enrollment: 424 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

CC-92480 Drug
Bortezomib Drug
Dexamethasone Drug
Daratumumab Drug
Carfilzomib Drug
Elotuzumab Drug
Isatuximab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 29, 2019
Primary completion: Nov 29, 2026
Completion: Nov 29, 2026
Last update posted: Nov 28, 2024

2019 – 2026

United States locations

U.S. sites: 16
U.S. states: 13
U.S. cities: 13

Facility	City	State	ZIP	Site status
Local Institution - 119	Denver	Colorado	80218	—
Local Institution - 104	Tampa	Florida	33612	—
Local Institution - 108	Atlanta	Georgia	30322	—
Local Institution - 112	Chicago	Illinois	60611	—
Local Institution - 107	Chicago	Illinois	60637	—
Local Institution - 117	Boston	Massachusetts	02114	—
Local Institution - 101	Boston	Massachusetts	02115	—
Local Institution - 118	Boston	Massachusetts	02215	—
Local Institution - 113	Detroit	Michigan	48201	—
Local Institution - 106	Rochester	Minnesota	55905	—
Hackensack University Medical Center	Hackensack	New Jersey	07601	—
Local Institution - 110	Winston-Salem	North Carolina	27157	—
Local Institution - 115	Columbus	Ohio	43210	—
Local Institution - 114	Nashville	Tennessee	37203	—
Local Institution - 116	Houston	Texas	77030	—
Swedish Cancer Institute	Seattle	Washington	98104	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03989414, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 28, 2024 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03989414 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →